This functional plasticity necessitates context-aware therapeutic strategies: PYK2 inhibition may be beneficial in cancers where it acts as an oncogenic scaffold (e.g., ESCC, HCC, PDAC), but could prove detrimental in GC where its tumor-suppressive functions are compromised by downregulation. This evidence concerns the gene PTK2B and cancer.